New antipsychotic medication

Krzysztof Wojtasik-Bakalarz; Marcin Siwek

doi:10.5114/fpn.2022.124608

eISSN: 2449-9315
ISSN: 1234-8279

Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

Open access

1/2023
vol. 39

Send email

Copy url:

abstract:

Review article

New antipsychotic medication

Krzysztof Wojtasik-Bakalarz

¹

,

Marcin Siwek

¹

Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Krakow, Poland; Zakład Zaburzeń Afektywnych, Katedra Psychiatrii, Uniwersytet Jagielloński – Collegium Medicum w Krakowie

Farmakoterapia w Psychiatrii i Neurologii 2023, 39 (1): 19-38

DOI: https://doi.org/10.5114/fpn.2022.124608

Online publish date: 2023/07/07

View full text Get citation

PlumX metrics:

Objectives.
The objective of this article was to present information concerning mechanisms of action, pharmacokinetics, clinical efficacy and tolerance of newly approved antipsychotic medication – lurasidone, brexpiprazole, cariprazine, lumateperone and pimavanserin – and to compare them with previously available ones.

Literature review.
We reviewed data from preclinical and clinical trials, literature reviews and meta-analyses concerning newly approved antipsychotic medication. We summarised information about pharmacodynamic effects, pharmacokinetics, clinical efficacy and tolerance of described medications.

Conclusions.
Newly approved antipsychotic medication seem to give hope of improvement of treatment efficacy, especially with regards to negative, cognitive and depressive symptoms of schizophrenia. They also seem to be better tolerated than previously available antipsychotics.

keywords:

New antipsychotic medication

Krzysztof Wojtasik-Bakalarz 1 , Marcin Siwek 1

brexpiprazole, cariprazine, lumateperone, lurasidone, pimavanserine

Krzysztof Wojtasik-Bakalarz

¹

,

Marcin Siwek

¹